pembrolizumab,enfortumab vedotin
seagen,astellas,merck
[' uc,(-ucsd),(-ucsf),', ' ev ', 'ev302', 'pembro']
randomised ii evp vs ev in 1st line uc (n=150). rr and cr rate of 65% ,11% for evp vs 45%, 4% for ev. mdfs and os are immature but looks better for evp for events number. pembro seems to ev early efficacy justifying the combination in r3 ev302 (evp vs chemo). #esmo22 
Interested in Urology Cancers, biomarkers and drug development.